Genital Wart Clinical Trial
Official title:
Comparison Between Tuberculin Vaccine and Cryotherapy in the Treatment of Genital Wart Patients
Verified date | May 2017 |
Source | Assiut University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Cutaneous and genital warts are common dermatological conditions caused by Human Papilloma Virus. Although it is a benign condition it causes disfigurement, has tendency to collect, can be transmitted to others, this makes adequate and timely treatment important, while many warts are resolve spontaneously over several years, most patients seek treatment because the warts are unsightly and often tender or painful.
Status | Not yet recruiting |
Enrollment | 45 |
Est. completion date | December 2018 |
Est. primary completion date | June 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years to 60 Years |
Eligibility |
Inclusion Criteria: - All types of genital and anal warts will be included in this study especially patients with 5 or more warts and more than 1 cm in size Exclusion Criteria: - Patients with immunodeficient diseases or receiving any immunosuppressive drugs - Pregnancy and lactation |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Assiut University |
Abd-Elazeim FM, Mohammed GF, Fathy A, Mohamed RW. Evaluation of IL-12 serum level in patients with recalcitrant multiple common warts, treated by intralesional tuberculin antigen. J Dermatolog Treat. 2014 Jun;25(3):264-7. doi: 10.3109/09546634.2013.768760 — View Citation
Bosch FX, de Sanjosé S. Chapter 1: Human papillomavirus and cervical cancer--burden and assessment of causality. J Natl Cancer Inst Monogr. 2003;(31):3-13. Review. — View Citation
Buck HW Jr. Genital warts. Clin Evid. 2006 Jun;(15):2149-61. Review. — View Citation
Horn TD, Johnson SM, Helm RM, Roberson PK. Intralesional immunotherapy of warts with mumps, Candida, and Trichophyton skin test antigens: a single-blinded, randomized, and controlled trial. Arch Dermatol. 2005 May;141(5):589-94. — View Citation
Scott M, Nakagawa M, Moscicki AB. Cell-mediated immune response to human papillomavirus infection. Clin Diagn Lab Immunol. 2001 Mar;8(2):209-20. Review. — View Citation
Sterling JC, Gibbs S, Haque Hussain SS, Mohd Mustapa MF, Handfield-Jones SE. British Association of Dermatologists' guidelines for the management of cutaneous warts 2014. Br J Dermatol. 2014 Oct;171(4):696-712. doi: 10.1111/bjd.13310. Epub 2014 Oct 1. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | number of patients with complete resolution of genital warts | frequency (number) | 4 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05518201 -
Evaluate the Safety and Immunogenicity of a 9-valent HPV Vaccine in Chinese Healthy Male Aged 9-45 Year-old
|
Phase 1 | |
Completed |
NCT05372016 -
Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
|
Phase 3 | |
Recruiting |
NCT05027776 -
Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years
|
Phase 3 | |
Active, not recruiting |
NCT05580341 -
Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9
|
Phase 3 | |
Completed |
NCT03676101 -
Evaluate the Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
|
Phase 1 | |
Recruiting |
NCT04895020 -
Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years
|
Phase 3 | |
Completed |
NCT04425291 -
Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
|
Phase 3 | |
Recruiting |
NCT05371353 -
Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine
|
||
Not yet recruiting |
NCT06454175 -
A Phase I Clinical Trial to Evaluate the Safety of 15-valent HPV Vaccine in Healthy Chinese People Aged 18-45 Years
|
Phase 1 | |
Not yet recruiting |
NCT06465914 -
A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males
|
Phase 3 | |
Active, not recruiting |
NCT04073082 -
Safety and Efficacy of Laser Therapy in Gynaecology
|
||
Completed |
NCT00999986 -
Low Dose Cyclophosphamide Treats Genital Warts
|
Phase 3 | |
Terminated |
NCT05584332 -
A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy Females
|
Phase 3 | |
Completed |
NCT04796090 -
Genital Wart and Sexuality in Adolescence
|
||
Enrolling by invitation |
NCT04905030 -
Education, Immigration and HPV Vaccination: an Informational Randomized Trial
|
N/A | |
Recruiting |
NCT04422366 -
Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
|
Phase 3 |